Is a new fast-acting pill for depression the Holy Grail that patients have been waiting for?

Is a new fast-acting pill for depression the Holy Grail that patients have been waiting for? Treating severe and chronic depression can be extremely difficult. Over the years, medicines have been developed to treat mood disorders, from tricyclics in the 1950s to SSRIs (selective serotonin reuptake inhibitors) in the 1970s.

However, it can take time for these drugs to have an effect (and in an estimated 30 per cent of cases, they don’t work at all); with SSRIs, it’s between four to eight weeks.

But could a new drug that’s just been approved by the Food & Drug Administration (FDA) in the U.S. be the answer? The Daily Mail

See also:

• FDA Approval of AUVELITY, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults Axsome Therapeutics
• Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI) (open access) Journal of Clinical Psychiatry